



Universidade Federal de Pelotas  
Centro de Ciências Químicas, Farmacêuticas e de Alimentos  
Programa de Pós-Graduação em Química  
Curso de Doutorado em Química  
Seminários II

***“Current and new drugs for the treatment of depression”***

It is estimated that 15% of adult population will experience depression at some time in their life. Nowadays this disease, according to the World Health Organization, affects 300 million people around the world. The depression is a mood disorder and a disabling disease, which can affect anyone at any age. If it takes its course without pharmacological intervention it will lead the patient to suicide. Therefore, it is essential to diagnose and to treat it. Currently, there are several pharmacological treatments available to treat the depressive condition, but, unfortunately, not all patients are responsive, thus the need to research for new molecules more active and, also with less collateral effects. The aim is to find compounds which are active on those for whom there is still no cure. In this context, the synthesis of new class of molecules, aralkyl piperazine derivatives, is reported as an example of novel compounds which could be used to develop a new generation of antidepressants.

**Laura Abenante**